/ /

CLINICAL

Building on cyclosporine for dry eyeA phase II study investigating a novel topical cyclosporine product (CyclASol, Novaliq) formulated in a semifluorinated alkane (SFA) vehicle showed promising efficacy, safety, and tolerability. Planning is ongoing for the phase III trial of cyclosporine in the SFA technology.
How wide-field SS-OCT expands spectrum of normal peripheral retinaWide-field retinal imaging can be performed using a commercially available swept-source optical coherence tomography (SS-OCT) platform (DRI OCT Triton, Topcon) and only the internal fixation light for patient navigation provided detailed images of both normal and pathologic peripheral retinal findings.
New hypersonic vitrector introduces concept of ‘vitreous liquefaction’
New hypersonic vitrector introduces concept of ‘vitreous liquefaction’A new hypersonic liquefaction vitrectomy system, called Vitesse PPVX (Bausch + Lomb), offers several advantages over currently available vitrector technology. The device received FDA 510k approval in April 2017.
How adaptive optics will change retinal imagingAdaptive optics could allow clinicians to monitor the progression of retinal diseases cell-by-cell, according to Jacque Duncan, MD.
Systemic safety of anti-VEGF treatment for ROP mandates further studyAccumulating evidence is cause for concern and underscoring the need for more research evaluating the safety of anti-VEGF injections for ROP, according to Robert L. Avery, MD.
Nystagmus diagnosis begins with thorough eye examA careful clinical workup, along with genetic testing, can help pinpoint what is behind congenital and infantile nystagmus.
ARVO 2017 showcases vision research advancesAdvances in presbyopia, dry eye and allergy, and age-related macular degeneration filled this year’s meeting of the Association for Research in Vision and Ophthalmology.
Sirolimus shows promise for posterior segment non-infectious uveitisIntravitreal sirolimus 400 mcg (Ospiria, Santen) demonstrated positive results in pivotal trials investigating it as a treatment for non-infectious uveitis of the posterior segment. A New Drug Application is under FDA review.
Multifunctional OCT system approval simplifies imagingA newly approved system (3D OCT-1 Maestro, Topcon) combines a high-resolution, color, non-mydriatric retinal camera with the latest spectral-domain optical coherence tomography (OCT) technology, and stands out for its versatility as well as its quality and ease of use.
Real-world outcomes with aflibercept better in treatment-naïve patientsAfter 12 months of treatment with intravitreal aflibercept injections, both treatment-naïve and pre-treated patients demonstrated visual acuity gains. Visual acuity improvement was higher in treatment-naïve patients.